Evidence map›Paper›PMID 38589887›Full record

ArticleCell communication and signaling : CCS2024

The protein composition of exosomes released by prostate cancer cells is distinctly regulated by androgen receptor-antagonists and -agonist to stimulate growth of target cells.

Golnaz Atri Roozbahani, Miriam Kokal-Ribaudo, Mehdi Heidari Horestani, Thanakorn Pungsrinont, Aria Baniahmad

Open access · goldAbstract read
In one paragraph

Article in Cell communication and signaling : CCS, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
3.3field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 14 citations in OpenAlex.

  1. Review
  2. Review
  3. Regulation of Cancer Metastasis by PAK2.International journal of molecular sciences · 2024
    Review
  4. Article
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Golnaz Atri RoozbahaniInstitute of Human Genetics, Jena University Hospital, Am Klinikum 1, 07740, Jena, Germany.
Miriam Kokal-RibaudoInstitute of Human Genetics, Jena University Hospital, Am Klinikum 1, 07740, Jena, Germany.
Mehdi Heidari HorestaniInstitute of Human Genetics, Jena University Hospital, Am Klinikum 1, 07740, Jena, Germany.
Thanakorn PungsrinontInstitute of Human Genetics, Jena University Hospital, Am Klinikum 1, 07740, Jena, Germany.
Aria BaniahmadInstitute of Human Genetics, Jena University Hospital, Am Klinikum 1, 07740, Jena, Germany. aria.baniahmad@med.uni-jena.de.
Jena University Hospital · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundProstate cancer (PCa) is a prevalent malignancy in men worldwide, ranking as the second leading cause of cancer-related death in Western countries. Various PCa hormone therapies, such as androgen receptor (AR)-antagonists or supraphysiological androgen level (SAL) reduce cancer cell proliferation. However, treated cells may influence the growth of neighboring cells through secreted exosomes in the tumor microenvironment (TME). Here, the change of protein content of exosomes secreted from PCa cells through treatment with different AR-antagonists or SAL has been analyzed.

methodsIsolation of exosomes via ultracentrifugation of treated human PCa LNCaP cells with AR-agonist and various AR-antagonists; analysis of cellular senescence by detection of senescence associated beta galactosidase activity (SA β-Gal); Western blotting and immunofluorescence staining; Mass spectrometry (MS-spec) of exosomes and bioinformatic analyses to identify ligand-specific exosomal proteins. Growth assays to analyze influence of exosomes on non-treated cells.

resultsMS-spec analysis identified ligand-specific proteins in exosomes. One thousand seventy proteins were up- and 52 proteins downregulated by SAL whereas enzalutamide upregulated 151 proteins and downregulated 42 exosomal proteins. The bioinformatic prediction indicates an up-regulation of pro-proliferative pathways. AR ligands augment hub factors in exosomes that include AKT1, CALM1, PAK2 and CTNND1. Accordingly, functional assays confirmed that the isolated exosomes from AR-ligand treated cells promote growth of untreated PCa cells.

conclusionThe data suggest that the cargo of exosomes is controlled by AR-agonist and -antagonists and distinct among the AR-antagonists. Further, exosomes promote growth that might influence the TME. This finding sheds light into the complex interplay between AR signaling and exosome-mediated communication between PCa cells.

Indexed as

ExosomesProstatic NeoplasmsAndrogen Receptor AntagonistsAndrogensCell Line, TumorHumansLigandsMaleReceptors, AndrogenTumor MicroenvironmentAndrogen Receptor AntagonistsAndrogensLigandsReceptors, AndrogenAndrogen receptor agonistAntagonistCellular senescenceExosomesExtracellular vesiclesProstate cancerSupraphysiological androgen levels

Identifiers

PMID38589887
PMCPMC11000412
OpenAlexW4394578045

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.